Preliminary laboratory tests have indicated that Sotrovimab performs best against the Omicron variant. This may be due to the fact that Sotrovimab was designed to target a part of the spike protein that did not mutate between previous coronavirus strains and the Omicron variant.
Read More »Read synopses of how each vaccine fares against the Omicron variant according to the latest data:
Read More »Yesterday, the FDA authorized COVID-19 booster shots for 16 and 17 year olds. Young adults in this age group who’ve received two shots of the Pfizer vaccine may now receive a third dose, 6 months after their primary series.
Read More »The WHO announced a new variant of concern last Friday. The Omicron variant has around 50 mutations from previous strains of the coronavirus, including over 30 mutations on the spike protein.
Read More »